Bicocca Open Archive

Logo unimib boa
LISSONI, ANDREA ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.768
AS - Asia 6.273
EU - Europa 4.846
SA - Sud America 1.039
AF - Africa 179
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 11
Totale 25.129
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.269
SG - Singapore 2.248
CN - Cina 1.387
IT - Italia 989
HK - Hong Kong 958
BR - Brasile 785
RU - Federazione Russa 781
VN - Vietnam 671
SE - Svezia 525
UA - Ucraina 516
DE - Germania 500
IE - Irlanda 474
CA - Canada 411
GB - Regno Unito 270
FR - Francia 220
IN - India 213
FI - Finlandia 150
AT - Austria 135
BD - Bangladesh 135
AR - Argentina 105
KR - Corea 104
TR - Turchia 80
ZA - Sudafrica 63
NL - Olanda 62
IQ - Iraq 61
PK - Pakistan 61
ID - Indonesia 56
MX - Messico 55
JP - Giappone 51
DK - Danimarca 45
PH - Filippine 44
ES - Italia 40
PL - Polonia 39
EC - Ecuador 36
CO - Colombia 34
SA - Arabia Saudita 33
MA - Marocco 31
VE - Venezuela 25
UZ - Uzbekistan 24
BE - Belgio 23
JO - Giordania 17
KE - Kenya 17
PY - Paraguay 16
AE - Emirati Arabi Uniti 14
CH - Svizzera 14
IR - Iran 14
CL - Cile 13
MY - Malesia 13
TN - Tunisia 13
EG - Egitto 12
TH - Thailandia 12
AU - Australia 11
UY - Uruguay 11
TW - Taiwan 10
ET - Etiopia 9
EU - Europa 9
IL - Israele 9
RO - Romania 9
AL - Albania 8
JM - Giamaica 8
PE - Perù 8
SN - Senegal 8
LT - Lituania 7
NP - Nepal 7
PS - Palestinian Territory 7
BO - Bolivia 6
DO - Repubblica Dominicana 6
DZ - Algeria 6
AZ - Azerbaigian 5
LB - Libano 5
OM - Oman 5
PA - Panama 5
RS - Serbia 5
CR - Costa Rica 4
CZ - Repubblica Ceca 4
MN - Mongolia 4
AO - Angola 3
BG - Bulgaria 3
BY - Bielorussia 3
GR - Grecia 3
HN - Honduras 3
KG - Kirghizistan 3
KH - Cambogia 3
KZ - Kazakistan 3
LA - Repubblica Popolare Democratica del Laos 3
NI - Nicaragua 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CI - Costa d'Avorio 2
CM - Camerun 2
CY - Cipro 2
EE - Estonia 2
GE - Georgia 2
HR - Croazia 2
HU - Ungheria 2
LK - Sri Lanka 2
LV - Lettonia 2
LY - Libia 2
MK - Macedonia 2
Totale 25.100
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.846
Singapore 1.250
Woodbridge 1.187
Ashburn 1.145
Hong Kong 935
Houston 681
Fairfield 676
San Jose 563
Jacksonville 523
Dublin 441
Chandler 414
Wilmington 401
Dearborn 335
Seattle 300
New York 298
Frankfurt am Main 297
Cambridge 255
Toronto 231
Princeton 218
The Dalles 214
Santa Clara 207
Chicago 206
Milan 193
Beijing 180
Ho Chi Minh City 178
Los Angeles 169
Hanoi 154
Dallas 147
Hefei 134
Vienna 122
Lauterbourg 109
Nanjing 109
Altamura 106
Lawrence 104
Lachine 91
Seoul 91
Shanghai 91
Moscow 77
Council Bluffs 72
São Paulo 71
Buffalo 52
Rome 51
Boardman 49
Fremont 49
Guangzhou 48
Andover 46
Helsinki 44
San Diego 44
Ottawa 41
London 39
Nanchang 38
Washington 38
Rio de Janeiro 37
Hebei 34
Munich 33
Changsha 31
Orem 30
Warsaw 30
Da Nang 29
Jakarta 29
Jiaxing 29
Shenyang 29
Tianjin 29
Tokyo 29
Baghdad 25
Johannesburg 25
Detroit 23
Salt Lake City 23
Brussels 22
Chennai 22
Huizen 22
Kunming 22
Nuremberg 22
Lahore 21
Pune 21
Tashkent 20
Brooklyn 19
Falls Church 19
Montreal 19
Atlanta 18
Norwalk 18
Ankara 17
Hangzhou 17
Lissone 17
Manchester 17
San Francisco 17
Amsterdam 16
Phoenix 16
Amman 15
Belo Horizonte 15
Bologna 15
Brasília 15
Haiphong 15
Denver 14
Dong Ket 14
Mexico City 14
Nairobi 14
Naples 14
Quito 14
Riyadh 14
Totale 16.380
Salva come PNG Salva come JPEG
Nome #
High-dose epirubicin in patients with advanced or recurrent uterine sarcoma 578
Oncologic and fertility impact of surgical approach for borderline ovarian tumours treated with fertility sparing surgery 540
Ovarian function, fertility, and menopause occurrence after fertility-sparing surgery and chemotherapy for ovarian neoplasms 427
Genomic and epigenomic profile of uterine smooth muscle tumors of uncertain malignant potential (Stumps) revealed similarities and differences with leiomyomas and leiomyosarcomas 405
Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production 396
Potential role of BCL2 in the recurrence of uterine smooth muscle tumors of uncertain malignant potential 379
Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers 360
Clinical outcome of patients with malignant tumors associated with mature cystic teratomas of the ovary: A retrospective multicenter Italian study 356
From Conventional Radiotracer Tc-99m with Blue Dye to Indocyanine Green Fluorescence: A Comparison of Methods Towards Optimization of Sentinel Lymph Node Mapping in Early Stage Cervical Cancer for a Laparoscopic Approach 340
Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer 336
OC13. 02: Reproducibility of IETA terms in describing endometrial pathology 308
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial 298
The paradigm shift in advanced ovarian cancer: Outcomes of extensive primary cytoreductive surgery. A single-center retrospective analysis 293
Imact of bevacizumab-containing primary treatment on outcome of recurrent ovarian cancer: An Italian study 292
Long-term toxicity and health-related quality of life after adjuvant chemoradiotherapy or radiotherapy alone for high-risk endometrial cancer in the randomised PORTEC-3 trial 286
Long-term clinical benefits of neoadjuvant chemotherapy in women with locally advanced cervical cancer: Validity of pathological response as surrogate endpoint of survival 283
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer 277
Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors 265
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective 264
Synchronous early-stage endometrial and ovarian cancer 264
Dose-dense neoadjuvant chemotherapy with paclitaxel and carboplatin in cervical cancer: Efficacy on pathological response 264
Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group 260
The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale 252
Uterine leiomyosarcoma: analysis of treatment failures and survival 252
Adjuvant sequential chemo and radiotherapy improves the oncological outcome in high risk endometrial cancer 251
Sentinel lymph node detection in endometrial cancer: hysteroscopic peritumoral versus cervical injection 249
Primary malignant vaginal melanoma treated with adriamycin and ifosfamide: a case report and literature review 246
Outcome of patients with stage I immature teratoma after surveillance or adjuvant chemotherapy 241
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study 239
A phase II clinical trial of topotecan and carboplatin in patients with newly diagnosed advanced epithelial ovarian cancer 238
Endometriomas: Their ultrasound characteristics 234
Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma 233
Early and short-term complications after US-guided puncture of gynecologic lesions: evaluation after 1,000 consecutive cases 232
Pre-operative morphological and colour Doppler features of borderline ovarian tumours 230
A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis 229
Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study 225
Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas 224
Proliferative response of lymphocytes from ovarian cancer patients to autologous tumor cells 224
Adnexal masses difficult to classify as benign or malignant using subjective assessment of gray-scale and Doppler ultrasound findings: logistic regression models do not help 224
Endometrial stromal sarcoma: analysis of treatment failures and survival 223
Fertility outcomes in stage I ovarian immature teratomas 222
Ultrasound characteristics of endometrial hyperplasia described using IETA terms 222
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel 220
Clindamycin-paclitaxel pharmacokinetic interaction in ovarian cancer patients 219
A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study 218
Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale 217
Brachytherapy for isolated vaginal recurrences from endometrial carcinoma 217
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial 216
Prospective multicenter study on CA 125 in postmenopausal pelvic masses 214
Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients 214
Neoadjuvant chemotherapy followed by radical surgery in locally advanced vulvar carcinoma: a single-institution experience 213
Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and of adjuvant radiation therapy 211
External validation of diagnostic models to estimate the risk of malignancy in adnexal masses 210
Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy 207
Ovarian cancer prediction in adnexal masses using ultrasound based logistic regression models: a temporal and external validation study by the IOTA group 206
Prospective multicenter study on the clinical utility of CA 72.4 in post-menopausal patients with pelvic mass 204
Optimal treatment of early-stage ovarian cancer 204
Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies 203
Machine Learning Application Identifies Germline Markers of Hypertension in Patients With Ovarian Cancer Treated With Carboplatin, Taxane, and Bevacizumab 202
Role of puncture and aspiration in expectant management of simple ovarian cysts: a randomised study 202
Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis 201
Intense neoadjuvant chemotherapy with cisplatin and epirubicin for advanced or bulky cervical and vaginal adenocarcinoma 201
International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer 199
Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study 198
Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes 197
Imaging in gynecological disease (7): clinical and ultrasound features of Brenner tumors of the ovary 197
Safety of transvaginal fine needle puncture of gynecologic masses: a report after 500 consecutive procedures 197
Ultrasound in the follow-up of young patients with malignant ovarian tumors after conservative surgery 193
Antiemetic efficacy of granisetron in patients with gynecological malignancies 192
Lesion size affects diagnostic performance of IOTA logistic regression models, IOTA simple rules and risk of malignancy index in discriminating between benign and malignant adnexal masses 192
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial 191
Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice 190
Primary carcinoma of the fallopian tube. A retrospective analysis of 47 patients 190
Color Doppler ultrasound in the preoperative assessment of adnexal masses 190
Tumor volume as risk factor for nodal diffusion in endometrial cancer 187
Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients 186
Effectiveness of autologous blood transfusion in patients undergoing radical hysterectomy 185
Changes in the management and outcome of central nervous system involvement from ovarian cancer since 1994 184
Modified radical hysterectomy versus extrafascial hysterectomy in the treatment of stage I endometrial cancer: results from the ILIADE randomized study 183
Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells 181
Clinically oriented three-step strategy for assessment of adnexal pathology 175
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial 175
The prognostic relevance of histological type in uterine sarcomas: A cooperation task force (CTF) multivariate analysis of 249 cases 172
Ifosfamide in the treatment of malignant epithelial ovarian tumors 171
A novel approach to predict the likelihood of specific ovarian tumor pathology based on serum CA-125: a multicenter observational study 171
Brain metastases from endometrial carcinoma 170
Unilocular adnexal cysts with papillary projections but no other solid components: Is there a diagnostic method that can classify them reliably as benign or malignant before surgery? 170
Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma 169
Second-look laparotomy in the management of fallopian tube carcinoma 167
Transvaginal ultrasonographic characterization of ovarian masses: comparison of five scoring systems in a multicenter study 167
Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas 163
Alpha-fetoprotein in the management of germ cell tumors of the ovary 156
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer 156
Fertility-sparing surgery in uterine leiomyosarcoma 155
Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer 155
Detection of abnormal intrauterine vascularization by color Doppler imaging: A possible additional aid for the follow up of patients with gestational trophoblastic tumors 151
Could different follow-up modalities play a role in the diagnosis of asymptomatic endometrial cancer relapses?: An Italian multicentric retrospective analysis 150
Total neuropathy scale items as early predictors of chemotherapy‐induced peripheral neurotoxicity 147
Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer 147
Response to chemotherapy and Clinical Outcome of Patients with recurrent epithelial ovarian cancer after PARP inhibitor maintenance treatment: a Multicenter retrospective italina Study 147
Totale 23.026
Salva come PNG Salva come JPEG
Categoria #
all - tutte 85.302
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 85.302
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021159 0 0 0 0 0 0 0 0 0 0 0 159
2021/20221.185 74 91 81 112 105 94 55 91 56 85 108 233
2022/20231.892 256 577 134 137 182 297 13 90 125 17 31 33
2023/20241.380 38 43 77 73 181 353 264 33 133 39 19 127
2024/20253.730 195 512 192 196 303 144 268 125 329 517 318 631
2025/20268.826 860 594 763 891 1.016 511 1.147 614 823 917 567 123
Totale 25.536